DNAs(Genentech) Avastin was approved about a year ago for use on colon cancer . The $11B jump was just for the new approval for Avastin on NSCLC . Indications are that Coramsine will raise the bar considerably higher again . It is my guess that Solbec will probably concentrate on orphan drug uses , such as melonoma and mesothelioma with the prospect of accellerated approval before trials are completed .
- Forums
- ASX - By Stock
- SBP
- genentech up $11 billion
SBP
solbec pharmaceuticals limited
genentech up $11 billion, page-4
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online